Nureca Ltd reported a turnaround in FY 2025-26, achieving a consolidated PAT of ₹2.08 crore and operating profit of ₹8.5 crore. The company is establishing a new manufacturing facility in Punjab to become an integrated healthcare products firm.
Nureca Ltd Reports FY26 Profitability Amidst Strategic Manufacturing Push
Consolidated PAT (FY 2026): ₹2.08 crore
Consolidated Revenue (FY 2026): ₹146.96 crore
Reader Takeaway: Operational turnaround with profit growth; Punjab plant key to future strategy.
What just happened
Nureca Limited has achieved a significant turnaround in its financial performance for the fiscal year 2025-26. The company reported a consolidated Profit After Tax (PAT) of ₹2.08 crore, a marked improvement from a loss in the previous year. This turnaround also saw an operating profit of ₹8.5 crore. Despite this overall positive trend, the company recorded a loss in the fourth quarter (Q4 FY 2026), primarily due to non-operating fair value losses on investments.
Why this matters
This financial recovery signifies improved operational efficiencies after three consecutive years of losses. The move back to profitability is a crucial indicator for investors. Furthermore, Nureca's strategic shift towards becoming an integrated healthcare products firm, supported by a new manufacturing facility, aims to reduce supply chain risks and enhance control over product quality.
The backstory
Nureca has been navigating a challenging period, marked by consecutive years of losses. The company is now actively transitioning its business model from a brand and distribution focus to a more integrated manufacturing approach for medical devices, consumables, and hygiene products.
What changes now
The company is developing a new manufacturing facility in Punjab, which will be central to its strategy of self-manufacturing. This will allow Nureca to reduce its reliance on international supply chains. Additionally, efforts to expand quick commerce presence continue to enhance delivery speeds.
Risks to watch
While the company has returned to profitability, the Q4 FY26 loss due to non-operating factors needs monitoring. The success of the new manufacturing facility in Punjab and leadership transitions are key factors that could impact future performance.
Peer comparison
(No peer comparison data available in the filing)
Context metrics (time-bound)
- Consolidated Revenue (FY 2026): ₹146.96 crore (up 34% YoY from ₹109.66 crore in FY 2025)
- Consolidated PAT (FY 2026): ₹2.08 crore (improved from ₹0.85 crore in FY 2025)
- Operating Profit (FY 2026): ₹8.5 crore (compared to a loss in the previous year)
- Share Buyback: 458,255 equity shares at ₹330 per share for ~₹15.12 crore (December 2025)
What to track next
Investors will be keen to observe the construction and operational ramp-up of the Punjab manufacturing facility. The integration of new leadership, following the resignations of the CFO and CEO, will also be closely watched for its impact on strategic execution.